The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Leerink Partners analyst Mani Foroohar has maintained their bullish stance on CRSP stock, giving a Buy rating on January 13.Stay Ahead of the ...

The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...

CRISPR Therapeutics AG (CRSP) closed the most recent trading day at $38.36, moving -1.26% from the previous trading session.

Lehigh University bioenginering researcher Tomas Gonzalez-Fernandez recently secured funding through the National Science ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Ongoing launch of CASGEVY® continues to gain momentum- -2025 is poised to be a catalyst-rich year with key updates across ...

If we assume all patients who began treatment with Casgevy last year progress to the administration stage, CRISPR and Vertex ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

Imagine a world where the genetic code is as easy to edit as a simple copy-and-paste. This is the reality of CRISPR, a ...